Literature DB >> 22580742

Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?

Christopher J Barnum1, Malú G Tansey.   

Abstract

Generally speaking, inflammation as a key piece to the Parkinson's disease (PD) puzzle is a relatively new concept. Acceptance of this concept has gained ground as studies by various researchers have demonstrated the potential of mitigating nigral cell death by curtailing inflammation in animal models of PD. We propose that the significance of inflammation in PD pathology may extend beyond the nigrostriatal region. In the current review, we present an argument for this based on the Braak staging and discuss how inflammation might contribute to the development of non-motor PD symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580742     DOI: 10.1007/s11910-012-0283-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  100 in total

1.  Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.

Authors:  Young C Chung; Sang R Kim; Ju-Young Park; Eun S Chung; Keun W Park; So Y Won; Eugene Bok; Minyoung Jin; Eun S Park; Sung-Hwa Yoon; Hyuk W Ko; Yoon-Seong Kim; Byung K Jin
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

2.  Inflammatory markers and neuropsychological functioning: the Framingham Heart Study.

Authors:  Angela L Jefferson; Joseph M Massaro; Alexa S Beiser; Sudha Seshadri; Martin G Larson; Philip A Wolf; Rhoda Au; Emelia J Benjamin
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

3.  Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.

Authors:  Sven Pålhagen; Hongshi Qi; Björn Mårtensson; Jan Wålinder; Ann-Kathrine Granérus; Per Svenningsson
Journal:  J Neurol       Date:  2009-10-21       Impact factor: 4.849

4.  The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.

Authors:  Matthew Menza; Roseanne Defronzo Dobkin; Humberto Marin; Margery H Mark; Michael Gara; Karina Bienfait; Allison Dicke; Alex Kusnekov
Journal:  Psychosomatics       Date:  2010 Nov-Dec       Impact factor: 2.386

5.  Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease.

Authors:  Yih-Ru Wu; I-Hsin Feng; Rong-Kuo Lyu; Kuo-Hsuan Chang; Yu-Yun Lin; Huiling Chan; Fen-Ju Hu; Guey-Jen Lee-Chen; Chiung-Mei Chen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-04-05       Impact factor: 3.568

6.  Microglia and memory: modulation by early-life infection.

Authors:  Lauren L Williamson; Paige W Sholar; Rishi S Mistry; Susan H Smith; Staci D Bilbo
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

Review 7.  IL-6 and its circadian secretion in humans.

Authors:  A N Vgontzas; E O Bixler; H-M Lin; P Prolo; G Trakada; G P Chrousos
Journal:  Neuroimmunomodulation       Date:  2005       Impact factor: 2.492

8.  Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.

Authors:  Anna Parachikova; Vitaly Vasilevko; David H Cribbs; Frank M LaFerla; Kim N Green
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

9.  Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.

Authors:  C J Barnum; K L Eskow; K Dupre; P Blandino; T Deak; C Bishop
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

10.  Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.

Authors:  Christopher B Forsyth; Kathleen M Shannon; Jeffrey H Kordower; Robin M Voigt; Maliha Shaikh; Jean A Jaglin; Jacob D Estes; Hemraj B Dodiya; Ali Keshavarzian
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

View more
  28 in total

1.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

2.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

Review 3.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

4.  Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.

Authors:  Hossein Sanjari Moghaddam; Zahra Valitabar; Amir Ashraf-Ganjouei; Mahtab Mojtahed Zadeh; Farzaneh Ghazi Sherbaf; Mohammad Hadi Aarabi
Journal:  Neuromolecular Med       Date:  2018-07-06       Impact factor: 3.843

5.  A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity.

Authors:  Ethan Stolzenberg; Deborah Berry; Ernest Y Lee; Alexander Kroemer; Stuart Kaufman; Gerard C L Wong; Joost J Oppenheim; Supti Sen; Thomas Fishbein; Ad Bax; Brent Harris; Denise Barbut; Michael A Zasloff
Journal:  J Innate Immun       Date:  2017-06-27       Impact factor: 7.349

6.  The Neuroinflammatory and Neurotoxic Potential of Palmitic Acid Is Mitigated by Oleic Acid in Microglial Cells and Microglial-Neuronal Co-cultures.

Authors:  Jimmy Beaulieu; Giulia Costa; Justine Renaud; Amélie Moitié; Hélène Glémet; Domenico Sergi; Maria-Grazia Martinoli
Journal:  Mol Neurobiol       Date:  2021-02-18       Impact factor: 5.590

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

Review 9.  Novel aspects of glucocorticoid actions.

Authors:  E T Uchoa; G Aguilera; J P Herman; J L Fiedler; T Deak; M B C de Sousa
Journal:  J Neuroendocrinol       Date:  2014-09       Impact factor: 3.627

10.  Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.

Authors:  Michael J Hurley; Pascal F Durrenberger; Steve M Gentleman; Andrew F Walls; David T Dexter
Journal:  J Mol Neurosci       Date:  2015-05-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.